方盛製藥(603998.SH):高血壓治療藥獲藥品註冊批件
格隆匯6月29日丨方盛製藥(603998.SH)公佈,公司收到國家藥監局核准簽發的《藥品註冊批件》,公司研發的厄貝沙坦氫氯噻嗪片已獲得藥品批准文號,並可進行生產。厄貝沙坦氫氯噻嗪片由賽諾菲公司研發,商品名為Coaprovel(安博維/安博諾),用於治療原發性高血壓。
目前,公司已着手安排生產,雖然我國心腦血管用藥市場較大,但該藥品未來的具體銷售情況可能受到市場環境變化等因素影響,具有不確定性,敬請廣大投資者謹慎決策,注意防範投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.